Artemisinin Antimalarial Drugs Market size was USD 702.5 million in 2024 and is estimated to reach USD 1.24 billion by the end of 2037, expanding at a CAGR of 4.5% during the forecast period, i.e., 2025-2037. In 2025, the industry size of artemisinin antimalarial drugs is assessed at USD 734.1 million.
The increasing prevalence of malaria is primarily augmenting the market growth worldwide. Underdeveloped and developing countries are mainly witnessing issues related to diseases caused by mosquitoes. For instance, according to a report by the World Health Organization (WHO), there were around 249 million cases of malaria, globally, in 2022. Such statistics underscore the need for effective treatment options, fuelling the market growth.
Africa is the most prevalent region for malaria, accounting for 94.0% of all malaria cases in 2022. The governments in the region are implementing several initiatives to increase disease awareness and care, this is generating lucrative opportunities for artemisinin antimalarial drug manufacturers.
Growth Drivers:
Challenges:
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.5% |
|
Base Year Market Size (2024) |
USD 702.5 million |
|
Forecast Year Market Size (2037) |
USD 1.24 billion |
|
Regional Scope |
|
Product (Antimalarial Injections, Antimalarial Tablets)
Antimalarial tablets segment is likely to account for more than 80.1% artemisinin antimalarial drugs market share by the end of 2037.The ongoing innovations in antimalarial tablet formulations are promoting their sales growth. The easy administration and high potential results are majorly driving the consumption of antimalarial tablets. Travelers often get affected by mosquito-related diseases including, malaria and to avoid any serious effects, they rely on antimalarial tablets. For instance, according to the U.S. Department of Veterans Affairs, mefloquine a white round tablet can help travelers to get cured of malaria infections.
Malaria Type (Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Ovale, Plasmodium Malariae, Plasmodium Knowlesi)
The plasmodium falciparum segment in artemisinin antimalarial drugs market is anticipated to capture a significant share of the global revenue by 2037 owing to the high prevalence of plasmodium falciparum and its severity. Plasmodium falciparum is a dominant parasite and accounts for a 65.8% prevalence rate, globally. Thus, such a high prevalence rate substantially drives the need for advanced medications including artemisinin-based combination therapies. Underdeveloped countries in Asia Pacific and MEA are particularly driving high demand for artemisinin antimalarial medications.
Our in-depth analysis of the global market includes the following segments:
|
Product |
|
|
Malaria Type |
|
|
Type |
|
Middle East and Africa Market Forecast
Middle East and Africa artemisinin antimalarial drugs market is set to account for revenue share of more than 33.8% by the end of 2037. The high prevalence of malaria and lack of hygiene in some parts of these regions particularly, in Africa is majorly fuelling the demand for advanced artemisinin antimalarial drugs.
Israel is one of the top markets for innovations in the medical device and pharma sectors, which is contributing to the development of advanced artemisinin antimalarial medications. The presence of advanced healthcare infrastructure and research organizations in the country is driving the sales of modern artemisinin antimalarial drugs. Israel has the world’s best and broadest health basket and according to the Government of Israel over 110 medical technologies and drugs were included in the basket at USD 178.5 million in 2024.
Nigeria is one of the African countries with a high burden of malaria, around 28% of the prevalence rate. International artemisinin antimalarial drug manufacturers are entering the Nigeria market to earn maximum revenue shares. The country is also carrying out several anti-malaria programs, which is fuelling the demand for injectable artemisinin antimalarial drugs.
Asia Pacific Market Statistics
Asia Pacific is foreseen to witness steady demand for artemisinin antimalarial drugs owing to the rise in malaria cases in some countries. China, Indonesia, and India are some of the economies with a high prevalence of malaria. The continuous innovations and malaria awareness programs are anticipated to boost the sales of artemisinin antimalarial drugs.
In India, the rising investments in healthcare infrastructure development and supportive government initiatives on malaria elimination are contributing to the market growth. For instance, the National Strategic Plan by India focuses on eliminating malaria by 2030.
Key players in the artemisinin antimalarial drugs market are investing heavily in the development of new formulations and delivery systems to enhance efficacy and patient compliance. They are also innovating fixed-dose combination therapies, which could enhance the effectiveness of treatment and aid in combating resistance. Industry giants are also collaborating with other players and research organizations to foster innovation and boost drug development. Furthermore, they are expanding into high-potential regions such as Asia Pacific, and Middle East & Africa where malaria prevalence is high to earn high profits.
Some of the key players include:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?